Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, No. 71 Hedi Road, Nanning, 530021, Guangxi, China.
Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning, 530021, Guangxi, China.
Hepatol Int. 2021 Feb;15(1):114-126. doi: 10.1007/s12072-020-10130-1. Epub 2021 Jan 25.
Portal vein tumor thrombus (PVTT) and microvascular invasion (MVI) are types of intrahepatic vascular metastasis of hepatocellular carcinoma (HCC) and are highly correlated with poor prognosis. However, the underlying biomarkers of PVTT and MVI are unclear.
We identified a PVTT/MVI-associated gene S100P by cDNA microarray analysis, and assess the potential value of serum S100P measurement in the differential diagnosis of HCC and prediction of MVI status with large retrospective and perspective cohort studies.
The mRNA and protein of S100P was increased in HCCs with PVTT or MVI. High S100P immunostaining in tumors was correlated with inferior tumor-free survival. Serum S100P values discriminated patients with HCCs from those with benign liver tumors, and it showed predictive potential of MVI status in both retrospective and perspective cohorts. S100P may regulate HCC tumorigenicity and invasive ability; S100P also was associated with up-regulation of CD44, which may mediate HCC cell adhesion to form PVTT/MVI.
Serum S100P may be a novel differential diagnostic marker for HCC and a potential predictor of MVI status pre-surgery for HCC patients. S100P overexpression in HCC is highly correlated with the formation of PVTT and MVI, which may make S100P as a potential therapeutic target for HCC metastasis.
门静脉癌栓（PVTT）和微血管侵犯（MVI）是肝细胞癌（HCC）肝内血管转移的两种类型，与预后不良密切相关。然而，PVTT 和 MVI 的潜在生物标志物尚不清楚。
我们通过 cDNA 微阵列分析鉴定出与 PVTT/MVI 相关的基因 S100P，并通过大型回顾性和前瞻性队列研究评估血清 S100P 测量在 HCC 鉴别诊断和 MVI 状态预测中的潜在价值。
PVTT 或 MVI 肝癌中 S100P 的 mRNA 和蛋白表达增加。肿瘤中高 S100P 免疫染色与无肿瘤生存不良相关。血清 S100P 值可区分 HCC 患者与良性肝肿瘤患者，且在回顾性和前瞻性队列中均显示出对 MVI 状态的预测潜力。S100P 可能调节 HCC 的肿瘤发生和侵袭能力；S100P 还与 CD44 的上调相关，这可能介导 HCC 细胞黏附形成 PVTT/MVI。
血清 S100P 可能是 HCC 的新型鉴别诊断标志物，也是 HCC 患者术前 MVI 状态的潜在预测指标。HCC 中 S100P 的过度表达与 PVTT 和 MVI 的形成高度相关，这使得 S100P 成为 HCC 转移的潜在治疗靶点。
